Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

Authors

M. von Mehren

Fox Chase Cancer Center, Philadelphia, PA

M. von Mehren , M. C. Heinrich , H. Joensuu , C. D. Blanke , E. Wehrle , G. D. Demetri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.

First Author: Axel Le Cesne

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).

First Author: Suzanne George

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.

First Author: D. Wang

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.

First Author: M. Ryu